Being diagnosed with and treated for cancer is highly stressful and potentially traumatic. An extensive literature has evaluated the prevalence, predictors, and correlates of cancer-related post-traumatic stress disorder (PTSD) symptoms and diagnoses. In this qualitative review of cancer-related PTSD literature, we highlight conceptual, methodological, and diagnostic issues, and identify clinical implications and areas for future research. Cancerrelated PTSD has been documented in a minority of patients with cancer and their family members, is positively associated with other indices of distress and reduced quality of life, and has several correlates and risk factors (eg, prior trauma history, pre-existing psychiatric conditions, poor social support). The literature on treatment of cancer-related PTSD is sparse. Existing literature on cancer-related PTSD has used DSM-IV-TR diagnostic criteria; the revised DSM-5 PTSD criteria have important implications for the assessment of cancer-related distress. Application of PTSD diagnosis to patients with cancer has been critiqued on conceptual and methodological grounds, and important diff erential diagnosis considerations should be taken into account. Psychosocial assessment of patients with cancer should include careful evaluation of pre-cancer diagnosis trauma and psychiatric history, and diagnostic interviewing should consider concurrent conditions (eg, adjustment disorder). Treatment of cancer-related PTSD should be approached with caution and be informed by existing evidence-based approaches for traumatic stress.
Introduction
Being diagnosed with and treated for cancer is highly stressful and potentially traumatic. Emotional responses to this experience can range from acute fear, sadness, and anger to enduring adjustment diffi culties, anxiety, and depression. On the basis of studies documenting traumatic stress-like reactions (eg, intrusive ideation, reactivity to reminders, avoidance) in patients with cancer, the DSM-IV-TR 1 post-traumatic stress disorder (PTSD) diagnostic criteria were expanded to include diagnosis and treatment of a life-threatening illness as a stressor that could elicit PTSD. An extensive literature emerged, evaluating the prevalence, predictors, and correlates of cancer-related PTSD symptoms and diagnoses. [2] [3] [4] [5] [6] [7] [8] [9] [10] PTSD has also been documented following myocardial infarction, cerebrovascular accidents, HIV infection, burns, and other medical stressors. [11] [12] [13] Changes in the DSM-5 14 PTSD diagnostic criteria have important implications for assessment of cancer-related PTSD, 15 but research with the updated criteria is limited. Here, we review cancer-related PTSD literature, highlight conceptual, methodological, and diagnostic issues, and identify clinical implications and areas for future research (panel 1).
Cancer as a traumatic stressor
Cancer diagnosis and treatment entail a series of stressors. For many, the cancer experience begins with detection of an abnormality on self-examination (eg, breast self-examination), a laboratory test (eg, prostatespecifi c antigen), screening procedure (eg, colonoscopy), routine imaging (eg, mammogram), or clinical examination (eg, skin cancer screening). A period of heightened anxiety follows during the progression of diagnostic, staging, and histology procedures. 16 Discovery that one has a life-threatening illness can be shocking and can undermine assumptions of invulnerability, predictability, and control. 17 Uncertainty, processing medical information, and complex decision making regarding treatment can make the early period of the illness trajectory particularly overwhelming. 18 Treatment of malignant disease might entail a series of acute and prolonged challenges, including surgery, chemotherapy, radiation, immunotherapy, and hormonal therapy and their related side-eff ects (eg, pain, disfi gurement, fatigue, gastrointestinal symptoms, skin irritation, hot fl ashes), as well as medical complications that occur as a result of the disease, treatment, or comorbid conditions. 8 More invasive treatments, including stem cell transplantation, might be life threatening. 19 Recurrent, metastatic disease has a poorer prognosis and more limited treatment options than does earlier-stage disease, and might occur in the context of an already arduous illness experience. 20 A substantial proportion of patients who transition to cancer survivor status face lingering fears of recurrence and residual Series physical and emotional sequelae. 21 Together, diagnosis and treatment of cancer pose a cascade of physical, emotional, practical, and social demands on the individual and their support network.
Evidence suggests that a substantial proportion of people with cancer might experience their diagnosis and treatment as traumatic. Several studies [22] [23] [24] using the DSM-IV-TR PTSD diagnostic criteria have asked patients with breast cancer if they experienced diagnosis and treatment of cancer as a threat to their life or physical integrity (criterion A1) and if they responded with fear, helplessness, or horror (criterion A2). Across these studies, 50-60% of respondents (34-46 patients) endorsed both criteria; perception of life threat was more common than were responses of fear, helplessness, or horror. Mehnert and Koch 25 found that cancer was a traumatic stressor for 69 (54%) of 127 patients with breast cancer. Andrykowski and colleagues 26 found that of 189 survivors of lung cancer, 70 (37%) patients endorsed diagnosis and treatment as a traumatic stressor using DSM-IV criteria, and 108 (57%) patients did so using DSM-5 diagnostic criteria. Similarly, Mulligan and colleagues 27 found that nearly half (70 of 170 patients) of a predominantly male sample of veterans with heterogeneous cancer types endorsed cancer as a traumatic stressor. Thus, evidence suggests that cancer might be experienced as traumatic by some-though not all-people who face cancer.
Prevalence and course
A substantial literature exists regarding estimated prevalence rates of cancer-related PTSD (table). Abbey and colleagues' meta-analysis 2 reviewed 25 studies (21 of which were of patients with breast cancer) of cancer-related PTSD in a total of 4189 adult cancer survivors. Prevalence rates varied widely depending on method of assessment. Studies using self-report PTSD symptom measures yielded prevalence estimates of clinically signifi cant symptom levels ranging from 7·3% (95% CI 4·5-11·7; ten studies) to 13·8% (9·5-19·6; 11 studies), depending on screening scoring method used. Investigations using more stringent, clinician-administered structured diagnostic interviews for PTSD yielded a lifetime prevalence estimate of 12·6% (7·4-20·7; seven studies) and a current prevalence estimate of 6·4% (4·1-9·9; 12 studies). 2 Other studies 22, 28 suggest that an additional 10-20% of patients with cancer might experience subsyndromal levels of PTSD symptoms and that subclinical posttraumatic stress symptoms are associated with distress and impaired quality of life.
The prevalence of cancer-related PTSD has also been evaluated in childhood cancer survivors and their parents. Bruce [30] [31] [32] of adult children of patients with cancer have found children's cancer-related PTSD screening rates to range from 13·3% (95% CI 5·0-21·6; 64 participants) to 19·4% (5·5-33·3; 31 participants). Evidence exists that parental pre-cancer diagnosis trauma history might increase risk for children's distress. 35 In an investigation 33 of 125 children with a sibling who had cancer, 28 (22·4%; 95% CI 14·7-29·3) children met PTSD criteria on a symptom report measure. Another study 34 found that eight (2·2%; 0·6-3·4) of 368 adult siblings of long-term cancer survivors met PTSD criteria. Thus, substantial empirical evidence suggests that cancer might elicit PTSD symptoms in patients and their family members.
Data regarding the course of cancer-related PTSD symptoms are sparse. Although some studies 36,37 suggest a decline in symptoms for most patients as time passes after diagnosis and treatment, others suggest an increase. 38, 39 One study 40 suggests fl uctuation of symptoms over the fi rst few years after diagnosis. Cancerrelated acute stress disorder appears to have modest predictive power for later development of cancer-related PTSD, and early dissociative symptoms have proven an even stronger predictor, whereas delayed-onset cancerrelated PTSD seems rare.
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Correlates of cancer-related PTSD
Correlates of cancer-related PTSD have been identifi ed (panel 2). Abbey and colleagues' meta-analysis 2 of studies of cancer-related PTSD in adult cancer survivors identifi ed young age, advanced disease, and recently completed treatment as risk factors for increased cancer-related PTSD (p values <0·05). These variables parallel Ozer and colleagues' review 41 of risk factors for PTSD in the general population (ie, young age, increased threat, recent trauma).
In addition, various individual studies have linked an array of other factors to cancer-related PTSD. For example, increased cancer-related PTSD has been associated with reduced income (univariate correlation coeffi cient [r]=−0·38) and education (r=−0·37), 42 increased precancer diagnosis personal life stressors and trauma exposure (r=0·23-0·27), 43, 44 past parental trauma exposure, 35 pre-cancer diagnosis mental health conditions, 37, 44 increased appraisal of cancer as a threat (r=0·30), 24 peritraumatic dissociation after cancer diagnosis (r=0·71), 36 acute stress reactions early in the cancer experience (r=0·48), 36 poor social support (r=−0·20), 45 increased social constraints (r=0·60), 24 low emotional self-effi cacy (standardised β=−0·46), 46 and avoidant coping (r=42). 47 Most of these variables correspond with established predictors of non-cancerrelated PTSD in adults; prior trauma, pre-existing mental health diffi culties, family history of psycho pathology, increased perceived threat posed by the trauma, poor post-trauma social support, and peritraumatic dissociation and distress have all been related to PTSD in the general population. 41 Research has also linked cancer-related PTSD to other indices of distress and functioning. Shand and colleagues' meta-analysis 9 of 26 studies that reported on association between cancer-related PTSD and other outcomes and variables of interest showed that cancer-related PTSD symptoms were positively correlated with depression (r=0·56, 95% CI 0·44 to 0·65; 11 studies, 1442 participants), anxiety (r=0·65, 0·50 to 0·76; seven studies, 1103 participants), and global distress (r=0·62, 0·55 to 0·69; eight studies, 968 participants), and negatively correlated with social support (r=−0·33, −0·48 to −0·17; four studies, 263 participants) and physical quality of life (r=−0·44, −0·60 to −0·24; seven studies, 980 participants). In this meta-analysis, cancer-related PTSD symptoms were weakly but positively correlated (r =0·13, 0·03 to 0·23; fi ve studies, 401 participants) with cancer-related post-traumatic growth-the perception of positive life changes due to a traumatic experience. 9 Few studies have examined the biological correlates of cancer-related PTSD. Yehuda 48 posited that the hypothalamic-pituitary-adrenal axis dysregulation seen in PTSD might be relevant to understanding cortisol changes in cancer. Luecken and colleagues 49 found that all-cause PTSD symptoms (including a few cases of cancer-related PTSD) in a sample of patients with breast cancer were associated with reduced levels of morning cortisol (r=−0·34). Glover and Poland's study 50 of mothers of survivors of paediatric cancer found that mothers with PTSD symptoms due to their child's cancer showed lower total urinary cortisol (p=0·01) and higher urinary norepinephrine (p=0·07) than did mothers without PTSD symptoms. Mothers with PTSD symptoms also showed a variety of indications of allostatic load. 51 Thomas and colleagues 52 evaluated female partners of patients with prostate cancer and found that women with at least subthreshold PTSD (most cases of which were is that threat and uncertainty posed by cancer and other life-threatening medical stressors might negatively aff ect health behaviour; however, the few studies that have attempted to evaluate this connection have not been conclusive. 55 
Conceptual, methodological, and diagnostic issues
The utility and appropriateness of the traumatic stressor construct and PTSD diagnosis in conceptualisation of cancer-related distress and adjustment diffi culties have been questioned. 15, 25, 56 Cancer is a multi-faceted, ambiguous, unfolding stressor rather than a discrete event that poses a clear and immediate threat. The initial stressor of diagnosis is primarily informational; 57 in many cases, patients are told of a potentially life-threatening condition that might not be causing physical symptoms or impairment at that moment. In addition, the threat posed by cancer-ie, malignant cells in the body-is largely internal, everpresent, and unavoidable. 7 Perhaps most importantly, even after treatment completion, cancer recurrence is a threat that requires ongoing vigilance and monitoring, 54 meaning survivors might never be post the experience of cancer. 5 Methodological limitations of existing studies of cancer-related PTSD further complicate the picture. To date, most studies have used the DSM-IV-TR diagnostic criteria for PTSD; as discussed below, the more stringent and expanded DSM-5 criteria have important implications for the assessment of cancer-related distress. 15 Most studies of cancer-related PTSD have been cross-sectional, precluding assessment of the onset and course of symptoms over time. In addition, existing studies of cancer-related PTSD have rarely evaluated pre-cancer-diagnosis, baseline psychiatric symptoms or comorbid conditions that have developed since cancer diagnosis; this information is needed to determine whether reports of cancer-related PTSD symptoms refl ect exacerbation of pre-existing distress or more general cancer-related adjustment diffi culties. 15 Samples of predominantly white female patients with breast cancer are over-represented in the existing cancer-related PTSD literature; the generalisability of these fi ndings to the broader population of patients with cancer is unclear. Most investigations have relied on self-report PTSD symptom measures; by contrast to gold-standard clinician-administered structured diagnostic interviews for PTSD, symptom measures might infl ate rates of PTSD caseness 2, 15 and fail to capture the specifi c nature of the perceived trauma and the frequency, severity, and functional impact of the symptoms in question. 7, 15 With DSM-5's shift to the Trauma-and Stressor-Related Disorders diagnostic category and revision of the PTSD diagnostic criteria, the applicability of PTSD diagnosis to cancer-related distress warrants further scrutiny, particularly with regard to diff erential diagnosis. 15 The Trauma-and Stressor-Related Disorders diagnostic category acknowledges the continuum of responses to stressful or traumatic events, from transient, normative emotional reactions to more substantial and impairing but time-limited adjustment disorders, and fi nally to more severe psychopathology, including acute stress disorder and PTSD. 15 Most studies of cancer-related PTSD have not also assessed for adjustment disorder, 15 even though this diagnosis appears to be more common than PTSD among patients with cancer 25, 58 and might be more appropriate for people with subsyndromal cancer-related PTSD symptoms, people experiencing more diff use symptoms of anxiety or depression regarding their cancer experience, and people whose cancer experience does not meet diagnostic criteria for a traumatic stressor.
Examination of the DSM-5 diagnostic criteria for PTSD 14 raises specifi c concerns regarding their application to patients diagnosed with and treated for cancer. 15 The so-called stressor criterion (criterion A) entails "exposure to actual or threatened death, serious injury, or sexual violence" in a variety of ways (eg, direct exposure, witnessing in person, learning of). The revision of criterion A from DSM-IV-TR to DSM-5 (ie, increasing objective threat and dropping subjective response) was intended to reduce subjectivity in determining whether a stressor was traumatic. The supporting text on diagnostic features in DSM-5 specifi cally states "A life-threatening illness or debilitating medical condition is not necessarily considered a traumatic event. Medical incidents that qualify as traumatic events involve sudden, catastrophic events." Thus, for the experience of cancer to meet criterion A, it must entail acute, severe complications or other extreme adverse events. Although such medical events seem to occur with regularity in the oncology setting, no research has been done on the proportion of patients for whom cancer would meet the DSM-5 stressor criterion.
If cancer does meet criterion A as a traumatic stressor, several additional criteria must be met to warrant a diagnosis of cancer-related PTSD.
14 These criteria include at least one intrusion symptom (criterion B), at least one avoidance symptom (criterion C), at least two symptoms refl ective of negative alterations in cognitions and mood (criterion D), and at least two arousal and reactivity symptoms (criterion E). This constellation of symptoms must be present for more than 1 month (criterion F), cause clinically signifi cant distress or impairment (criterion G), and not be caused by the physiological eff ects of a substance (including medication) or a medical condition (criterion H).
Application of these criteria to patients with cancer requires attention to detail and phenomenology, with Series distinction between psychopathological and normative responses to cancer diagnosis and treatment. For instance, fears of future recurrence, disease progression, and death are common among patients with cancer and diff er from intrusive memories or re-experiencing of cancer-related stressors that have already occurred. 15, 54 Similarly, avoidance reactions must be in response to traumatic memories of past cancer-related events, rather than feared, anticipated future events. Various alternative explanations to PTSD for negative alterations in cognitions or mood might exist. Specifi cally, an inability to recall certain aspects of the cancer experience might be due to neurocognitive side-eff ects of treatment, blaming of oneself for the diagnosis might be realitybased (eg, smoking leading to lung cancer, excessive alcohol use leading to cirrhosis and hepatocellular cancer), and diminished interest in previously enjoyed activities might be due to practical obstacles, symptoms or side-eff ects of treatment, or shifts in values and goals. With regard to arousal and reactivity symptoms, concentration and sleep diffi culties are common treatment side-eff ects among patients with cancer and might not be indicative of traumatic stress reactions. 5 Foundational to these points is the fact that cancer represents an existential threat. It is not unrealistic or distorted for people facing cancer to recognise and worry that their disease might shorten their life, to think more about their death, and to question their relationships, their values, and the assumptions they hold about control and predictability of their lives. 17, 59 Indeed, patients with cancer commonly report existential angst, death anxiety, aloneness, and a sense of loss of meaning, freedom, and control. 59 Thus, pathologisation of normative responses to the cancer experience should be avoided.
Although this existential threat can lead to extreme distress, it can also prompt shifts in priorities and values, views of self and others, and sense of meaning and spirituality.
Post-traumatic growth 60 -which has alternately been referred to as stress-related growth, benefi t fi nding, perceived benefi ts, growth through adversity, and existential growth-has been studied in a broad range of populations of patients with cancer. This multi-dimensional construct includes perceived positive changes in personal strength, new possibilities, relating to others, appreciation of life, and spiritual change. 60 Although fi ndings regarding the relationship between cancer-related post-traumatic growth and cancer-related PTSD have been inconsistent, 9,61,62 the perceived threat posed by cancer might set the stage for both to occur. 24, 26 In light of these conceptual, methodological, and diagnostic issues, careful diagnostic interviewing, history taking, and broad assessment of functioning are essential and might result in more conservative and appropriate application of the cancer-related PTSD diagnosis. Such an approach might also paint a more complete picture of psychosocial functioning that includes both psychological distress and positive aspects of wellbeing and growth.
Implications for practice
Literature on cancer-related PTSD has important implications for clinical practice. First, integration of psychosocial assessment and support into oncology care settings is essential, both in active treatment 63 and survivorship 64 phases of care. Many patients with cancer undergoing treatment do not have the time or energy to seek care in a separate mental health setting; embedding psycho-oncology specialists in medical settings is crucial to patient-centred care.
Second, assessment of patients' psychiatric and trauma histories should be a standard part of the history and physical. Given the predictive power of previous trauma history for development of PTSD symptoms in response to cancer 44, 65, 66 and the possibility that the uncertainty, perceived threat, and sensory stimuli (eg, smells, body sensations) related to cancer might be a trigger of prior trauma symptoms, the context in which the cancer experience is playing out needs to be understood. This information could be collected by the treating physician or by an embedded mental health clinician. Such careful evaluation at initial clinic visits can help to determine whether current distress is an exacerbation of a pre-existing condition, a rekindling of PTSD symptoms related to a prior trauma, or a new response to the cancer diagnosis and treatment. 15 Third, ongoing screening for distress is a key component of the National Comprehensive Cancer Network's clinical practice guidelines, and clinical pathways for management of acute stress, traumatic stress, and adjustment disorders have been specifi ed. 67 Routine assessment of distress via the National Comprehensive Cancer Network's distress thermometer and accompanying problem checklist can detect patients with elevated psychosocial concerns. More formal diagnostic assessment of specifi c psychiatric symptoms, including depression, anxiety, and PTSD, can follow.
Fourth, the applicability of evidence-based psy chotherapeutic PTSD treatments (eg, prolonged exposure 68 or cognitive processing therapy 69 ) to cancer-related PTSD should be carefully considered. Indeed, PTSD-specifi c interventions have shown utility in patients with cancer. Kangas and colleagues' randomised trial 70 found that early administration of a cognitive behavioural therapy (CBT) intervention-with components of imaginal and in-vivo exposure-was more eff ective than supportive therapy in reducing total (ie, including re-experiencing, avoidance or numbing, and arousal symptom clusters) PTSD symptoms at 12-month follow-up in patients with head and neck cancer (67% improved vs 20% improved). DuHamel and colleagues 71 found that a ten-session, telephone-based CBT intervention designed to address cancer-related PTSD was more eff ective than was an assessment-only control condition in reduction of Series intrusive ideation (p<0·05), avoidance (p<0·001), and general distress and depression (p<0·05) in haemapoietic stem-cell transplant survivors. Eye movement desensitisation and reprocessing (EMDR) 72 interventions have also shown promise in reduction of cancer-related PTSD symptoms (p<0·001), 73 although the mechanisms of EMDR are unclear. 74 Supportive expressive group therapy 59 has reduced re-experiencing and avoidance symptoms in women with metastatic breast cancer (eff ect size 0·25, p=0·03). 75 Interventions that were not necessarily designed to address cancer-related PTSD have shown positive eff ects. Approaches that include CBT components have yielded some positive eff ects. 76 Cognitive behavioural stress management 77 interventions have shown benefi cial eff ects on intrusive thoughts (eff ect size 0·55) 78 and total PTSD symptoms (eff ect size 1·02) 79 in women with breast cancer. Other coping skills-based approaches have been shown to reduce total PTSD symptoms.
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A couples-based coping intervention reduced avoidance symptoms in patients with breast and gynaecological cancer (eff ect size 0·34-0·39). 81 Mindfulness-based approaches have also had a positive eff ect on cancer-related avoidance (eff ect size 0·41) and hyperarousal (eff ect size 0·07-0·41) symptoms. 82 Promising interventions-still requiring rigorous evaluation-for illness-related traumatic stress include narrative therapy 83 and dyadic interventions that promote emotional disclosure. 84, 85 Fifth, caution is advised in application of general PTSD medication guidelines to patients with cancerrelated PTSD. Pharmacotherapy for cancer-related PTSD has received very little research attention. Lindgren and colleagues 86 found that β blockers appeared to reduce intrusive ideation by 32% in newly diagnosed patients with cancer (p<0·05). We could not identify any other pharmacological treatment trials for cancer-related PTSD.
The literature off ers some guidance on the management of cancer-related anxiety and sleep disruption. A range of classes of medications has been used for cancer-related anxiety, including antidepressants, benzodiazepines, and non-benzodiazepine anxiolytics, with benzodiazepines also being used for symptom management (eg, nausea, insomnia). 87 Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are used for long-term anxiety in patients with cancer. 88 Clonidine, an α-adrenergic agonist, has been used to reduce sympathetic outfl ow, peripheral vascular resistance, and catecholamine output. 89 Prazosin, an α 1 -adrenergic receptor antagonist, and trazodone, an antidepressant that selectively inhibits serotonin uptake, decrease nightmares and improve sleep quality. 90, 91 High-level evidence supports use of eszopiclone, risperidone, and olanzapine as an adjunct therapy in treatment for PTSD-related insomnia and nightmares. 92 Davidson 93 develops a case that tricyclic antidepressants deserve to be re-examined in PTSD, noting the residual morbidity of many patients with poor response to the current evidence-based therapies, although these therapies are more strongly anticholinergic and far more dangerous in overdose than are SSRIs or SNRIs.
Prior trauma history appears to have important implications for the use of psychoactive medication and psychotherapy with PTSD. Nemeroff and colleagues' dismantling study 94 of combined psychotherapy and antidepressant medication in patients with chronic depression showed that, overall, the combination worked better than either therapy alone; however, patients with a history of childhood trauma responded more positively to psychotherapy than to antidepressant medication, and con versely, patients with no trauma history responded more positively to medication than to psychotherapy. These results suggest that a history of childhood trauma indicates a need for intensive psychotherapy, even when anti depressant medication is used. This consideration is especially important for patients with cancer, given fi ndings that such a diagnosis might trigger a recurrence of prior trauma-related symptomatology-eg, among Holocaust survivors. 66 Drug-drug interactions between psychotropics and cancer agents are potential problems. 95 Some antidepressants, such as fl uoxetine, fl uvoxamine, and paroxetine, might lower serum concentrations of endoxifen-the active tamoxifen metabolite-reducing the eff ectiveness of the drug. Sertraline, citalopram, escitalopram, and venlafaxine generally have a lesser eff ect on tamoxifen metabolism. 96 Benzodiazepines should be used with caution in medical patients given the risks for adverse drug eff ects (eg, gait impairment, psychomotor slowing), motor vehicle and other accidents, unsafe behaviours, dependency, tolerance, delirium, and withdrawal. 97 
Conclusion
Being diagnosed with and treated for cancer is highly stressful and might lead to persistent psycho pathology in a minority of patients. The application of the PTSD diagnosis to cancer-related adjustment diffi culties is not without controversy. Thoughtful and careful assessment and development of appropriate treatment pathways can optimise detection and management of distress and traumatic stress in the oncology setting.
Search strategy and selection criteria
We identifi ed articles by searching several databases, including Ovid MEDLINE, PsycINFO, PsycARTICLES, Psychology and Behavioral Sciences Collection, and Academic Search Complete. We did updated searches for all languages from Jan 1, 1989, to July 1, 2016. For each search, all relevant subject headings and free text terms were used to represent "PTSD" AND "cancer". The total number of references retrieved was 1637.
